A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling
- PMID: 19681898
- DOI: 10.1111/j.1464-410X.2009.08778.x
A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling
Abstract
Study type: Diagnostic (exploratory cohort).
Level of evidence: 2b.
Objective: To develop a nomogram to predict the probability that the pathological Gleason sum (GS) will be higher than that indicated by the biopsy, suggesting a higher risk for the patient presumed to be at low risk, as a substantial proportion of patients with low and intermediate grade on biopsy are upgraded on interpretation of the radical prostatectomy (RP) specimens, but a similar clarification of accurate Gleason scoring is not available in patients with no surgical histology.
Patients and methods: The study included 1017 patients who had RP after biopsy showing GS 6 and 7 (3 + 4) from 2000 to 2007. Nomogram predictor variables included age, race, digital rectal examination, prostate-specific antigen (PSA) level, number of cores taken, number of positive cores, maximum percentage cancer in any core, number of previous biopsies, prostate volume, clinical stage, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, inflammation and perineural invasion. We calculated the nomogram-predicted probability in each patient. The area under the receiver operating characteristic curve was calculated as a measure of discrimination, and the calibration was assessed graphically.
Results: The mean age of the patients was 60 years, the mean PSA level 6.62 ng/mL; 336 patients were upgraded (33%), 623 remained the same (61.3%) and 58 were downgraded (5.7%). A nomogram for predicting the possibility of upgrading was constructed that had a concordance index of 0.68. The nomogram was well calibrated.
Conclusions: Our nomogram for predicting upgrading provides important additional information for deciding on treatment to both the urologist and the patient with low- and intermediate-grade prostate cancer. It might prove useful when the possibility of a more aggressive Gleason variant can change the management, and is especially meaningful when management options other than surgery are selected based on the inability to recognize the true pathological actual GS.
Similar articles
-
Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.BJU Int. 2009 Jan;103(1):43-8. doi: 10.1111/j.1464-410X.2008.08059.x. Epub 2008 Sep 8. BJU Int. 2009. PMID: 18782303
-
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.BJU Int. 2006 Aug;98(2):329-34. doi: 10.1111/j.1464-410X.2006.06262.x. BJU Int. 2006. PMID: 16879673
-
The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15. BJU Int. 2012. PMID: 22085203
-
A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.Cancer. 2007 Dec 1;110(11):2441-7. doi: 10.1002/cncr.23055. Cancer. 2007. PMID: 17932909
-
Comparisons of nomograms and urologists' predictions in prostate cancer.Semin Urol Oncol. 2002 May;20(2):82-8. doi: 10.1053/suro.2002.32490. Semin Urol Oncol. 2002. PMID: 12012293 Review.
Cited by
-
The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes.Cancers (Basel). 2022 Dec 30;15(1):262. doi: 10.3390/cancers15010262. Cancers (Basel). 2022. PMID: 36612262 Free PMC article.
-
Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.Asian J Androl. 2022 Sep-Oct;24(5):487-493. doi: 10.4103/aja2021108. Asian J Androl. 2022. PMID: 35170453 Free PMC article.
-
Prostate Cancer Gleason Score From Biopsy to Radical Surgery: Can Ultrasound Shear Wave Elastography and Multiparametric Magnetic Resonance Imaging Narrow the Gap?Front Oncol. 2021 Nov 23;11:740724. doi: 10.3389/fonc.2021.740724. eCollection 2021. Front Oncol. 2021. PMID: 34888237 Free PMC article.
-
Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort.Cancer Med. 2021 Nov;10(21):7772-7780. doi: 10.1002/cam4.4274. Epub 2021 Sep 16. Cancer Med. 2021. PMID: 34528767 Free PMC article.
-
Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.BMC Urol. 2021 Jan 6;21(1):3. doi: 10.1186/s12894-020-00773-5. BMC Urol. 2021. PMID: 33407381 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
